Business context and reporting period
Banco Bradesco S.A. filed this Form 6-K on October 2, 2026, reporting the completion and Board ratification of its capital increase through subscription of new shares. This is a corporate-capital update, not a periodic earnings report.
Capital increase and key figures
- The Board ratified a capital increase of R$10.0 billion, fully subscribed through 604,852,753 new shares: 302,876,396 common and 301,976,357 preferred.
- Issue prices were R$15.43 per common share and R$17.64 per preferred share.
- An auction of remaining unsubscribed shares sold all receipts offered, representing 1,505,454 common shares at R$15.50 each and 14,553,057 preferred shares at R$17.86 each. The stated gross auction amount was R$283,252,135.02.
- The additional R$3,307,054.32 premium from the auction, equivalent to R$0.07 per common share and R$0.22 per preferred share, will be allocated to a capital reserve.
- After approval by Brazil’s Central Bank (BACEN), share capital is expected to increase from R$93.77 billion to R$103.77 billion. The resulting total of 11,196,864,781 shares is expected to comprise 5,606,747,177 common and 5,590,117,604 preferred shares.
Operating performance and comparison
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-performance metrics, nor a comparable-period analysis. The reported change is the planned increase in share capital, pending BACEN ratification.
Outlook, conditions, and risks
The capital increase remains subject to BACEN ratification. Following ratification, the new shares are to be credited to subscribers within three business days and will be entitled to the full amount of dividends, interest on shareholders’ equity, and other distributions declared from that date. The company said it will report BACEN’s decision.
The filing includes general forward-looking-statement cautions: expectations are based on assumptions about economic, market, industry, and operating conditions, and actual events or results may differ materially. No specific operating guidance is provided.
Important facts for investors to verify
- Whether and when BACEN ratifies the capital increase.
- Completion of share issuance and subscriber crediting, and the final post-increase share count.
- The treatment and allocation of the auction proceeds and premium as described in the filing.
- Any subsequent company disclosures regarding dividends or other distributions applicable to the new shares.